Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Daptomycin | 2 | 2019 | 29 | 1.280 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 743 | 1.280 |
Why?
|
| Muscular Diseases | 2 | 2019 | 61 | 1.240 |
Why?
|
| HIV Infections | 2 | 2021 | 353 | 1.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 137 | 1.170 |
Why?
|
| Bacteremia | 3 | 2022 | 90 | 1.100 |
Why?
|
| Acinetobacter Infections | 1 | 2024 | 8 | 0.940 |
Why?
|
| Carbapenems | 1 | 2024 | 16 | 0.930 |
Why?
|
| Acinetobacter baumannii | 1 | 2024 | 12 | 0.930 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 95 | 0.930 |
Why?
|
| Cephalosporins | 1 | 2024 | 38 | 0.920 |
Why?
|
| Respiratory Tract Infections | 5 | 2016 | 76 | 0.870 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 271 | 0.860 |
Why?
|
| Sex Offenses | 1 | 2021 | 74 | 0.710 |
Why?
|
| Coronavirus | 1 | 2020 | 16 | 0.700 |
Why?
|
| Shock, Septic | 1 | 2021 | 78 | 0.700 |
Why?
|
| Myocarditis | 1 | 2020 | 44 | 0.680 |
Why?
|
| Rhabdomyolysis | 1 | 2018 | 12 | 0.630 |
Why?
|
| Influenza, Human | 2 | 2016 | 83 | 0.620 |
Why?
|
| Sepsis | 1 | 2021 | 220 | 0.610 |
Why?
|
| RNA, Viral | 4 | 2016 | 124 | 0.610 |
Why?
|
| Virus Diseases | 2 | 2016 | 39 | 0.600 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 287 | 0.580 |
Why?
|
| RNA Stability | 1 | 2016 | 24 | 0.530 |
Why?
|
| Specimen Handling | 1 | 2016 | 54 | 0.530 |
Why?
|
| Cross Infection | 1 | 2016 | 94 | 0.520 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 594 | 0.480 |
Why?
|
| Humans | 25 | 2024 | 49863 | 0.420 |
Why?
|
| Spiders | 1 | 2012 | 9 | 0.410 |
Why?
|
| Spider Venoms | 1 | 2012 | 6 | 0.410 |
Why?
|
| Lip | 1 | 2012 | 10 | 0.400 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 30 | 0.400 |
Why?
|
| Bites and Stings | 1 | 2012 | 22 | 0.390 |
Why?
|
| Anaphylaxis | 1 | 2012 | 71 | 0.380 |
Why?
|
| Coronavirus Infections | 2 | 2016 | 179 | 0.340 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6106 | 0.320 |
Why?
|
| Acanthamoeba | 1 | 2008 | 2 | 0.310 |
Why?
|
| DNA Viruses | 1 | 2008 | 3 | 0.310 |
Why?
|
| Pneumonia | 2 | 2010 | 117 | 0.300 |
Why?
|
| Paramyxoviridae Infections | 1 | 2006 | 3 | 0.280 |
Why?
|
| Metapneumovirus | 1 | 2006 | 5 | 0.280 |
Why?
|
| Nasopharynx | 1 | 2006 | 25 | 0.280 |
Why?
|
| Whooping Cough | 1 | 2006 | 11 | 0.280 |
Why?
|
| Lung Transplantation | 1 | 2006 | 37 | 0.270 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 118 | 0.260 |
Why?
|
| Sulbactam | 1 | 2024 | 5 | 0.240 |
Why?
|
| Azabicyclo Compounds | 1 | 2024 | 11 | 0.240 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2024 | 21 | 0.240 |
Why?
|
| Pneumonia, Viral | 1 | 2007 | 170 | 0.230 |
Why?
|
| Male | 9 | 2024 | 25439 | 0.230 |
Why?
|
| DNA Transposable Elements | 1 | 2024 | 105 | 0.230 |
Why?
|
| Middle Aged | 7 | 2024 | 12258 | 0.230 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 63 | 0.230 |
Why?
|
| Retinal Vessels | 1 | 2024 | 14 | 0.230 |
Why?
|
| Fluorescein Angiography | 1 | 2024 | 33 | 0.230 |
Why?
|
| Female | 9 | 2024 | 26520 | 0.220 |
Why?
|
| Syphilis | 1 | 2024 | 27 | 0.220 |
Why?
|
| Eye Infections, Bacterial | 1 | 2024 | 32 | 0.220 |
Why?
|
| Receptors, Cell Surface | 1 | 2024 | 123 | 0.220 |
Why?
|
| Risk Factors | 3 | 2021 | 3597 | 0.220 |
Why?
|
| Tomography, Optical Coherence | 1 | 2024 | 104 | 0.210 |
Why?
|
| Adult | 9 | 2024 | 13325 | 0.210 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2022 | 42 | 0.200 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2021 | 4 | 0.200 |
Why?
|
| Staphylococcus | 1 | 2021 | 35 | 0.200 |
Why?
|
| HIV | 1 | 2021 | 25 | 0.200 |
Why?
|
| Hospitalization | 3 | 2021 | 663 | 0.190 |
Why?
|
| Aftercare | 1 | 2021 | 74 | 0.190 |
Why?
|
| Aged | 4 | 2021 | 9434 | 0.170 |
Why?
|
| Immunoglobulins | 1 | 2020 | 79 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2021 | 317 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 459 | 0.160 |
Why?
|
| Tennessee | 1 | 2018 | 36 | 0.160 |
Why?
|
| Creatine Kinase | 1 | 2018 | 30 | 0.160 |
Why?
|
| Registries | 1 | 2021 | 522 | 0.160 |
Why?
|
| Electrocardiography | 1 | 2020 | 259 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2008 | 855 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2020 | 228 | 0.150 |
Why?
|
| Viral Matrix Proteins | 2 | 2008 | 10 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 487 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 380 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 453 | 0.140 |
Why?
|
| Ribonuclease P | 1 | 2016 | 3 | 0.140 |
Why?
|
| Influenza B virus | 1 | 2016 | 6 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2018 | 209 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2016 | 17 | 0.130 |
Why?
|
| Logistic Models | 1 | 2018 | 895 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 181 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1129 | 0.130 |
Why?
|
| Age Factors | 2 | 2016 | 1091 | 0.120 |
Why?
|
| Rural Population | 2 | 2010 | 546 | 0.120 |
Why?
|
| Thailand | 2 | 2010 | 8 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 2889 | 0.100 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2010 | 12 | 0.090 |
Why?
|
| DNA, Viral | 2 | 2008 | 133 | 0.090 |
Why?
|
| Rickettsia felis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Rickettsia Infections | 1 | 2010 | 3 | 0.090 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2010 | 34 | 0.090 |
Why?
|
| Viremia | 1 | 2008 | 22 | 0.080 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 27 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 34 | 0.080 |
Why?
|
| Organ Transplantation | 1 | 2008 | 47 | 0.070 |
Why?
|
| Rhinovirus | 1 | 2007 | 22 | 0.070 |
Why?
|
| Picornaviridae Infections | 1 | 2007 | 18 | 0.070 |
Why?
|
| Young Adult | 3 | 2012 | 4013 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2008 | 107 | 0.070 |
Why?
|
| RNA Virus Infections | 1 | 2007 | 2 | 0.070 |
Why?
|
| RNA Viruses | 1 | 2007 | 7 | 0.070 |
Why?
|
| Respiratory Tract Diseases | 1 | 2007 | 26 | 0.070 |
Why?
|
| Self-Sustained Sequence Replication | 1 | 2006 | 1 | 0.070 |
Why?
|
| Nucleoproteins | 1 | 2006 | 2 | 0.070 |
Why?
|
| Arkansas | 1 | 2012 | 1982 | 0.070 |
Why?
|
| Adolescent | 4 | 2010 | 6392 | 0.060 |
Why?
|
| Animals | 2 | 2012 | 13133 | 0.060 |
Why?
|
| Fractals | 1 | 2024 | 8 | 0.060 |
Why?
|
| Chorioretinitis | 1 | 2024 | 9 | 0.060 |
Why?
|
| Microvessels | 1 | 2024 | 29 | 0.060 |
Why?
|
| Infant | 2 | 2010 | 3565 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2010 | 3872 | 0.050 |
Why?
|
| Visual Acuity | 1 | 2024 | 140 | 0.050 |
Why?
|
| Child | 3 | 2010 | 6838 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2023 | 517 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 223 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 2174 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 409 | 0.040 |
Why?
|
| Kenya | 1 | 2010 | 10 | 0.020 |
Why?
|
| United States | 1 | 2021 | 4870 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2010 | 187 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 160 | 0.020 |
Why?
|
| Automation | 1 | 2008 | 17 | 0.020 |
Why?
|
| Enterovirus | 1 | 2007 | 4 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2007 | 31 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 982 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 237 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2007 | 123 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2008 | 161 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 791 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 907 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2010 | 2725 | 0.010 |
Why?
|